Background: GBC is a rare disease and chemotherapy in this setting lacks a standardized approach.
Patients And Methods: Patients 16-30 weeks pregnant with locally advanced/metastatic disease or with high risk of recurrence after surgery were evaluated.
Results: Twenty patients received weekly epirubicin 35 mg/m(2). Median maternal age was 37 years (23-42). Median gestational age at chemotherapy was 19 weeks. Thirteen patients were treated after surgery while 7 had locally advanced tumours of which one had liver metastases. Mean total epirubicin dose was 420 mg/m(2) with a median number of 12 administrations (4-16). No grade 3-4 toxicities were observed. No foetal adverse events were observed except 1 premature delivery at 28 weeks. Births were induced by caesarean section in 12 patients at a median gestational age of 35 weeks. No malformations were reported except 1 newborn with polycystic kidney. At a median age of 2 years, neurological, cardiological and immunological development was normal in all children as reported by their parents. In 7/20 patients with evaluable disease, five had an objective response. At a median follow-up of 38 months, 17 patients are alive; 14 are disease free.
Conclusions: Weekly epirubicin appears safe and effective with low foetal toxicity and could be considered in GBC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10549-008-0159-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.
J Surg Oncol
October 2024
Department of General Surgery, School of Medicine, Koç University, Istanbul, Turkey.
Article Synopsis
- The FLOT 4-AIO trial demonstrated that a docetaxel-based treatment was more effective than an epirubicin-based regimen for patients with locally advanced resectable gastric cancer, but many patients didn't complete the full treatment plan of eight cycles.
- This study compared total neoadjuvant therapy (FLOT x8) with the standard approach (FLOT 4+4) to see which method improved treatment completion and tumor downstaging for patients with advanced gastric tumors prior to surgical removal.
- Results showed that the FLOT x8 group had a significantly higher completion rate of 89.1% compared to 67.6% in the FLOT 4+4
Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy.
Acta Oncol
August 2024
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden; Department of Medicine and Oncology, Södra Älvsborgs Hospital, Borås, Sweden.
Background And Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a troublesome side effect in patients exposed to taxanes in the treatment of cancer and may affect quality of life dramatically. Here we assessed whether serum levels of neurofilament light (NfL) and tau (two neuroaxonal injury biomarkers) and glial fibrillary acidic protein (GFAP, a biomarker for astrocytic activation) correlate with the development of CIPN in the adjuvant setting of early breast cancer.
Materials And Methods: Using ultrasensitive single molecule array technology, serum levels of NfL, GFAP, and tau were measured before and every 3 weeks in 10 women receiving adjuvant EC (epirubicin 90 mg/m² and cyclophosphamide 600 mg/m²) every 3 weeks × 3, followed by weekly paclitaxel 80 mg/m² × 9-12 weeks after surgery due to early breast cancer.
Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study.
EClinicalMedicine
August 2024
Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Article Synopsis
- A phase II trial was conducted to evaluate the efficacy and safety of a new neoadjuvant chemoimmunotherapy regimen combining chemotherapy with the PD-1 antibody toripalimab for early-stage triple-negative breast cancer (TNBC).
- The study included 70 female patients with stage II-III TNBC, who received a combination of standard chemotherapy and immunotherapy, with primary endpoints focusing on total and breast pathological complete response rates.
- Results showed that over half of the participants achieved tumor response, with some experiencing manageable side effects, indicating that this treatment combination is promising and worthy of further research.
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
BMC Urol
May 2023
Department for BioMedical Research, Translational Organoid Resource Core, University of Bern, Bern, Switzerland.
Background: In intermediate-risk non-muscle invasive bladder cancer (NMIBC) clinical guidelines suggest an adjuvant instillation with a chemotherapeutic agent. However, the agent and regimen are not clearly defined. Worldwide, less than 15% of patients receive this adjuvant chemotherapeutic instillation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!